| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $42.7M | +2984.7% |
| SG&A Expense | $19.4M | +920.0% |
| Operating Income | -$75.0M | +14.0% |
| Net Income | -$79.4M | +11.6% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $64.7M | +15.7% |
| Short-term Investments | $40.0M | +0.0% |
| Current Assets | $66.5M | -32.5% |
| Total Assets | $124.8M | -16.1% |
| Current Liabilities | $24.9M | -2.2% |
| Stockholders' Equity | -$8.0M | -118.3% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$70.4M | +13.9% |
| Capital Expenditures | $6.4M | -57.8% |
| Investing Cash Flow | $34.0M | +155.9% |
| Financing Cash Flow | $45.1M | -36.8% |
| Free Cash Flow | -$76.8M | +20.7% |